Table 3: Tyrosine hydroxylase (TH) in brain and apomorphine-induced contralateral rotation after intravenous injection of gene therapy with TH expression plasmids.

Treatment (group)Days after RxApomorphine revolutions before RxApomorphine revolutions after RxStriatal TH (pmol/h/mgp)

Saline3   324 ± 69*401 ± 72162 ± 36
6232 ± 43342 ± 62288 ± 42
10228 ± 23331 ± 55120 ± 18

Clone 8773196 ± 24      56 ± 20b   4286 ± 918b
6231 ± 47 230 ± 55   1015 ± 213a
10219 ± 35 256 ± 27   335 ± 79a

prgTH23251 ± 38   123 ± 31b      1343 ± 176b,c
6295 ± 55   119 ± 34a   1535 ± 324b
10344 ± 27   443 ± 70c   884 ± 7b,d

prgTH33317 ± 23   234 ± 38d   167 ± 35d
6197 ± 11   127 ± 11a      545 ± 117a
10202 ± 31   111 ± 9b,d         985 ± 101b,d

prgTH43211 ± 28100 ± 9b      1219 ± 137b,c
6234 ± 37   113 ± 20b   1621 ± 196b
10      3 ± 64 249 ± 64   500 ± 86b

NoneNA005068 ± 168

Rx: single IV injection of TfRMAb-targeted THLs encapsulating the respective TH expression plasmid. *Mean ± S.E. ( –6 rats per point). Statistically significant differences were determined by Student’s t-test.
Clone 877 is the TH expression plasmid driven by the SV40 promoter. For details in the engineering of TH genomic vectors, clones prgTH2–TH4, please see Figure 5.
Difference with saline: a; b.
Difference with clone 877: c; d.
NA: not applicable.
From [48].